Showing papers by "Timothy M. Uyeki published in 2002"
TL;DR: In this paper, the authors conducted four retrospective cohort studies of persons exposed to these two H9N2 patients to assess whether human-to-human transmission of avian H 9N2 viruses had occurred.
Abstract: In April 1999, isolation of avian influenza A (H9N2) viruses from humans was confirmed for the first time. H9N2 viruses were isolated from nasopharyngeal aspirate specimens collected from two children who were hospitalized with uncomplicated, febrile, upper respiratory tract illnesses in Hong Kong during March 1999. Novel influenza viruses have the potential to initiate global pandemics if they are sufficiently transmissible among humans. We conducted four retrospective cohort studies of persons exposed to these two H9N2 patients to assess whether human-to-human transmission of avian H9N2 viruses had occurred. No serologic evidence of H9N2 infection was found in family members or health-care workers who had close contact with the H9N2-infected children, suggesting that these H9N2 viruses were not easily transmitted from person to person.
91 citations
01 Jan 2002
TL;DR: No serologic evidence of H9N2 infection was found in family members or health-care workers who had close contact with the H 9N2-infected children, suggesting that these H9n2 viruses were not easily transmitted from person to person.
89 citations
TL;DR: This work has shown a clear relationship between the prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C infection and the RT-PCR status and mode of acquisition and the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syndrome.
Abstract: 1. De Meirleir K, Suhadolnik RJ, Lebleu B, Englebienne P. Antiviral pathway activation in chronic fatigue syndrome and acute infection [letter]. Clin Infect Dis 2002; 34:1420–1 (in this issue). 2. Gow JW, Simpson K, Behan PO, Chaudhuri A, McKay IC, Behan WMH. Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. Clin Infect Dis 2001; 33:2080–1. 3. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–9. 4. De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99–105. 5. Suhadolnick RJ, Reichenbach NL, Hilzges P, et al. Upregulation of the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18:S96–104. 6. Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of protein degradation. Pharmacol Ther 1998; 78:55–113. 7. Suhadolnick RJ, Peterson DL, O’Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A–dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Research 1997; 17:377–85. 8. Goulding C, et al. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C infection” relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13:507–11.
4 citations